Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/8988
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSetiawan, Budi-
dc.contributor.authorA. Pangarsa, Eko-
dc.contributor.authorSantosa, Damai-
dc.date.accessioned2024-12-14T03:45:13Z-
dc.date.available2024-12-14T03:45:13Z-
dc.date.issued2022-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/8988-
dc.description.abstractThromboembolism events, either venous (VTE) or arterial thromboembolism (ATE) remain a highly prevalent complication in cancer patients. Thrombosis is a leading cause of death, contributor to significant morbidity, the reason of delayed cancer treatment, leading to increased cancer financing and expenses. Both cancer and its treatment are recently found to be related to vascular inflammation through the induction of tissue factor (TF) expression and promoting a procoagulant state which triggers the activation of coagulation system. Several risk factors may also coexist such as dehydration, immobilization, smoking, obesity, previous DVT, etc. Even in patients with asymptomatic deep vein thrombosis (DVT), they have a three-fold increase in mortality. The high morbidity and mortality of VTE raises the need for thromboprophylaxis to reduce the incidence of overt thrombosis, albeit against its possible side effects related to anticoagulant prescription. This article highlighted the clinical perspectives for thromboprophylaxis while counting on the risk stratification in a particular cancer patient. Keywords: thrombosis, cancer, inflammation, thromboprophylaxisen_US
dc.subjectthrombosis, cancer, inflammation, thromboprophylaxisen_US
dc.titlePreventing Thrombosis in Cancer Patientsen_US
dc.typeArticleen_US
Appears in Collections:VOL 54 NO 4 2022

Files in This Item:
File Description SizeFormat 
15.crdownload592.29 kBUnknownView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.